Trial Profile
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Prednisolone (Primary) ; Secukinumab (Primary) ; Vitamin D
- Indications Giant cell arteritis
- Focus Proof of concept; Therapeutic Use
- Acronyms TitAIN
- Sponsors Novartis Pharmaceuticals
- 04 Jun 2022 Results assessing efficacy, safety, and tolerability of secukinumab in Giant Cell Arteritis patients, presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 09 Nov 2021 Results presented at the ACR Convergence 2021
- 17 Aug 2021 Trial design published in the Trials.